BA202

BA202 is a bispecific T-cell engager (TCE) being developed by T-Cypher Bio for the treatment of solid tumors. The molecule is designed to target the PRAME (Preferentially Expressed Antigen in Melanoma) antigen when presented by the HLA-A2 MHC class I molecule on the surface of tumor cells. By simultaneously binding to the CD3 receptor on T cells, BA202 facilitates the recruitment and activation of cytotoxic T lymphocytes directly to the tumor site, leading to the selective lysis of PRAME-expressing cancer cells. This approach allows for the targeting of intracellular proteins that are otherwise inaccessible to conventional monoclonal antibodies. BA202 is currently in the lead optimization stage of development.

Other names

BA202-T-Cypher Bio-PRAME A2-CD3-T cell engager-bispecific antibody-Solid tumorsBA-202-T-Cypher Bio-PRAME A2-CD3-T cell engager-bispecific antibody-Solid tumorsBA 202-T-Cypher Bio-PRAME A2-CD3-T cell engager-bispecific antibody-Solid tumors